www.harvardcbe.org Open in urlscan Pro
34.149.87.45  Public Scan

Form analysis
0 forms found in the DOM

Text Content

top of page
Skip to Main Content


 * Clients

 * Industries
   
   * Technology
   * Life Sciences
   * Sustainability

 * Impact
   
   * Scholarships
   * Sustainability Grant
   * Ventures
   * Black Solidarity Grant

 * Our Team
   
   * Executive Team
   * Analysts

 * Contact

 * Blog

 * Apply

 * More


Use tab to navigate through the menu items.



THE STATE OF THE LIFE SCIENCES


NEW HEALTH ECONOMY

The U.S. Life Sciences industry has been under many different pressures: in the
forms of cost, government regulations, and operational barriers. These
challenges are called the New Health Economy, which also includes hospital
consolidation (intended for efficiency gains), changing demands and expectations
of patients, and increasing calls for price reforms. This has pushed many
industry towards collaboration amongst one another as well as a more
consumer-facing industry.

DATA DRIVEN

Emphasis on personalized treatments that can benefit individuals – flexible and
interactive.

GEOGRAPHIES

Costs are rising as geographic clusters form in expensive areas like the Bay
Area and Boston.



EXTERNAL FACTORS

Inventions, insurance rates, pandemics – all of these can drastically change the
future of the industry.


INDUSTRY REPORTS

ENGINEERED CELL THERAPY

December 2021

View the report

OBESITY MARKET

December 2019

View the report

GENE THERAPY
MARKET

September 2020

View the report


SELECT CLIENT SECTORS

PHARMACEUTICALS

Pharmaceutical companies have recently undergone a wave of mega-mergers,
particularly focused on strengthening research pipelines in oncology and
immunology. In addition, the industry has been shifting towards expanding the
role of data to accelerate research and aid business decisions. Data based
approaches have enabled better predictive models, more effective clinical
trials, and targeted marketing.

BIOTECHNOLOGY

As treatment platforms expand beyond traditional large-molecule therapies to
fields such as monoclonal antibodies, bispecific antibodies, and nucleic acid
therapies, the biotech field is filled with exciting potential. In particular,
gene and cell therapy are becoming central sub-sectors that are driving
partnerships and consolidations with big pharma. Additionally, increasing
computational research capabilities and enhanced data collection methods are
revealing vast new insights from genomic, expression, and mutation datasets.

MEDICAL DEVICES

With a growing elderly population and increasing demand for noninvasive
therapies, the potential for medical device innovation in traditional healthcare
settings is promising. These prospects are bolstered by recent efforts by the
Food & Drug Administration (FDA) and the Centers for Medicare & Medicaid
Services (CMS) to facilitate the process of medical device approval. Mobile
health services are also projected to expand rapidly in the coming years. These
products could revolutionize care coordination outside of healthcare facilities,
provide digital therapies, and enhance user health on a day-to-day basis.

DIGITAL HEALTH

While big data has become increasingly adopted by other industries, the
healthcare industry has been slow to adopt many digital solutions. Nonetheless,
the implementation of data-driven health solutions can further personalize care
and enhance medical insights throughout a patient’s treatment. While the path to
success is riddled with challenges in data aggregation, patient privacy, data
management, and regulations, the developments of these digital systems have vast
potential to drive analytical healthcare innovation.

HARVARD CONSULTING ON BUSINESS AND THE ENVIRONMENT © 2022

bottom of page